Loading...
•
Sep 30, 2020
Lyra Q3 2020 Earnings Report
Reported financial results and provided a corporate update.
Key Takeaways
Lyra Therapeutics reported its Q3 2020 financial results, highlighting that the company is on track to report topline Phase 2 results for LYR-210 in December 2020. The company's cash position is expected to fund operations through a planned Phase 3 study of LYR-210.
On track to report topline Phase 2 results for LYR-210 in December 2020.
Nancy L. Snyderman appointed to the Board of Directors.
Presented clinical data at the 66th Annual Meeting of the American Rhinologic Society (ARS) demonstrating LYR-210’s local anti-inflammatory effects.
Cash, cash equivalents as of September 30, 2020 were $81.6 million.
Forward Guidance
Lyra believes its current cash position is sufficient to fund the company through a planned Phase 3 study of LYR-210 in chronic rhinosinusitis. Additionally, the company projects its year-end 2020 cash balance will be in the range of $67-70 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...